Fig. 3From: Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phaseOne-way sensitivity analysis for the impact of the overall survival on the incremental cost-effectivenessBack to article page